Sox9 is required for prostate development and prostate cancer initiation

Zhenhua Huang; Paula J. Hurley; Brian W. Simons; Luigi Marchionni; David M. Berman; Ashley E. Ross; Edward M. Schaeffer

doi:10.18632/oncotarget.531

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Sox9 is required for prostate development and prostate cancer initiation

Zhenhua Huang _, Paula J. Hurley, Brian W. Simons, Luigi Marchionni, David M. Berman, Ashley E. Ross and Edward M. Schaeffer

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2012; 3:651-663. https://doi.org/10.18632/oncotarget.531

Metrics: PDF 3430 views | HTML 3552 views | ?

Abstract

Zhenhua Huang^1,2,3, Paula J Hurley¹, Brian W Simons^1,2,3, Luigi Marchionni^2,3, David M Berman^1,2,3, Ashley E Ross¹ and Edward M Schaeffer^1,2,3

¹ Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

² Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

³ Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Received: June 26, 2012; Accepted: June 30, 2012; Published: July 2, 2012;

Keywords: Sox9, prostate, development, cancer, initiation

Correspondence:

Edward M Schaeffer, email:

Abstract

Prostate cancer is one of the most common malignancies and the second leading cause of death from cancer in men. The molecular mechanisms driving prostate carcinogenesis are complex; with several lines of evidence suggesting that the re-expression of conserved developmental programs plays a key role. In this study, we used conditional gene targeting and organ grafting, to describe conserved roles for the transcription factor Sox9 in the initiation of both prostate organogenesis and prostate carcinogenesis in murine models. Abrogation of Sox9 expression prior to the initiation of androgen signaling blocks the initiation of prostate development. Similarly, Sox9 deletion in two genetic models of prostate cancer (TRAMP and Hi-Myc) prevented cancer initiation. Expression profiling of Sox9-null prostate epithelial cells revealed that the role of Sox9 in the initiation of prostate development may relate to its regulation of multiple cytokeratins and cell adherence/polarity. Due to its essential role in cancer initiation, manipulation of Sox9 targets in at-risk men may prove useful in the chemoprevention of prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 531

Publication Alerts

Research Papers:

Sox9 is required for prostate development and prostate cancer initiation

Abstract